Sumitomo Pharma (Suzhou) Co., Ltd. clinical trials
Formerly part of Sumitomo Pharma Co., Ltd., Jul 31, 2025 · source ↗
The registry lists 13 studies whose lead sponsor is Sumitomo Pharma (Suzhou) Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 19, 2024.
Before and after it left Sumitomo Pharma Co., Ltd.
- First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- 13
- First submitted after Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Sumitomo Pharma (Suzhou) Co., Ltd.13 studies
Something wrong with this grouping? Tell us on the Sumitomo Pharma Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All Sumitomo Pharma Co., Ltd. studies →
- The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From OlanzapineTerminatedNCT05213143Phase 4
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia PatientsTerminatedNCT03784222Phase 4
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With SchizophreniaCompletedNCT05011669Phase 4
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia PatientsCompletedNCT04432688
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I DepressionTerminatedNCT04383691Phase 3
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety DisorderCompletedNCT01614041Phase 4
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- A Clinical Trial of Lurasidone in Treatment of SchizophreniaCompletedNCT02002832Phase 3
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis PatientsCompletedNCT01351636Phase 4
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart RateCompletedNCT02612298Phase 4
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human SubjectsCompletedNCT02174523Phase 1
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy SubjectsCompletedNCT02174510Phase 1
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With RisperidoneCompletedNCT01516424Phase 3
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.
- Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung CancerCompletedNCT00660504Phase 3
Sponsor listed in the registry: Sumitomo Pharma (Suzhou) Co., Ltd. · First submitted before Sumitomo Pharma (Suzhou) Co., Ltd. left Sumitomo Pharma Co., Ltd.